Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 15.3% in April

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) saw a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 9,400 shares, a decrease of 15.3% from the March 31st total of 11,100 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily trading volume, of 31,300 shares, the short-interest ratio is presently 0.3 days.

Institutional Trading of Sol-Gel Technologies

A hedge fund recently bought a new position in Sol-Gel Technologies stock. Yelin Lapidot Holdings Management Ltd. acquired a new position in shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 229,178 shares of the company’s stock, valued at approximately $374,000. Yelin Lapidot Holdings Management Ltd. owned 0.99% of Sol-Gel Technologies as of its most recent SEC filing. Hedge funds and other institutional investors own 26.18% of the company’s stock.

Sol-Gel Technologies Trading Down 18.7 %

Shares of SLGL opened at $0.71 on Wednesday. The company’s fifty day simple moving average is $1.00 and its 200-day simple moving average is $1.18. The company has a market cap of $19.85 million, a P/E ratio of -0.77 and a beta of 1.33. Sol-Gel Technologies has a twelve month low of $0.71 and a twelve month high of $4.05.

Sol-Gel Technologies (NASDAQ:SLGL) last announced its quarterly earnings data on Wednesday, March 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). Sol-Gel Technologies had a negative return on equity of 61.52% and a negative net margin of 1,331.01%. The firm had revenue of $0.45 million during the quarter, compared to the consensus estimate of $0.27 million. Analysts predict that Sol-Gel Technologies will post -0.67 earnings per share for the current fiscal year.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.